54 Investor presentation First three months of 2021 Saxenda ® addresses a global unm management Global obesity prevalence Saxenda ® launched c <10% <10-19.9% <20-29.9% >30% Saxenda ® now launched in NAO: North America Operations; IO: International Operations; EMEA: Europe, Middle East and Africa; RoW: Rest of World; NICE: Nat Source: World Health Organisation (WHO) – Global Health Observatory, 2016. Obesity defined as BMI > 30 (BMI: Body Mass Index)
Download PDF file